Evidence map›Paper›PMID 42425088›Full record

ArticleStem cell reports2026

The role of gastric cancer patient-derived organoids in precision medicine: Clinicians' perspective.

Tharindie N Silva, Harleen Kaur, Tharani Krishnan, David S Liu, Margaret Lee, Markus Trochsler, Nicholas J Clemons, Josephine A Wright, Susan L Woods, Gastric Cancer Organoid Survey group

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cell reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Tharindie N SilvaAdelaide Medical School, Adelaide University, Adelaide, SA, Australia; Precision Cancer Medicine Theme, South Australia Health and Medical Research Institute, Adelaide, SA, Australia.
Harleen KaurAdelaide Medical School, Adelaide University, Adelaide, SA, Australia; Precision Cancer Medicine Theme, South Australia Health and Medical Research Institute, Adelaide, SA, Australia; Department of Surgery, Adelaide University, The Queen Elizabeth Hospital Adelaide, Woodville South, SA, Australia.
Tharani KrishnanCollege of Medicine and Public Health, Flinders University, Bedford Park, SA, Australia; Department of Medical Oncology, Flinders Medical Centre, Bedford Park, SA, Australia.
David S LiuDivision of Cancer Surgery, The Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Victorian Interventional Research and Trials Unit, Department of Surgery, The University of Melbourne, Heidelberg, VIC, Australia; Upper Gastrointestinal Surgery Unit, Austin Health, Heidelberg, VIC, Australia.
Margaret LeeDepartment of Medical Oncology, Western Health, Melbourne, VIC, Australia.
Markus TrochslerDepartment of Surgery, Adelaide University, The Queen Elizabeth Hospital Adelaide, Woodville South, SA, Australia.
Nicholas J ClemonsCancer Research Division, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia.
Josephine A WrightPrecision Cancer Medicine Theme, South Australia Health and Medical Research Institute, Adelaide, SA, Australia.
Susan L WoodsAdelaide Medical School, Adelaide University, Adelaide, SA, Australia; Precision Cancer Medicine Theme, South Australia Health and Medical Research Institute, Adelaide, SA, Australia. Electronic address: susan.woods@adelaide.edu.au.
Gastric Cancer Organoid Survey group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Organoid technology holds great potential and hope for personalized treatment in gastric cancer (GC). To date, clinicians' views on this technology for precision oncology have not been reported despite these insights being invaluable to understanding how organoids may be effectively integrated into clinical practice. Hence, we explored clinicians' knowledge and perception of organoid research and its potential clinical utility in GC treatment. Clinicians believed that organoids would be most useful for guiding adjuvant treatment in patients who fail neoadjuvant therapy and emphasized the importance of obtaining results within 4-6 weeks of surgical resection. Clinicians also expressed concerns and suggestions related to current research methodologies and highlighted the ethical and political aspects of organoid-guided personalized medicine. Overall, most clinicians perceived the value in the use of organoids to guide personalized treatment in GC and provided important insights into how this approach could be best implemented in clinical practice in the future.

Indexed as

OrganoidsPrecision MedicineStomach NeoplasmsHumansclinician perspective surveygastric cancerorganoidsprecision medicine

Identifiers

PMID42425088
PMCPMC13476899

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.